These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 9109153

  • 1. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura.
    Pool V, Chen R, Rhodes P.
    Pediatr Infect Dis J; 1997 Apr; 16(4):423-4. PubMed ID: 9109153
    [No Abstract] [Full Text] [Related]

  • 2. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO, Kapustik LA, Fel'dman EV, Ermolovich MA, Svirchevskaia EIu, Titov LP, Zakharenko DF, Belova EIu, Chernovetskiĭ MA, Korostik TS.
    Zh Mikrobiol Epidemiol Immunobiol; 1998 Apr; (4):36-40. PubMed ID: 9783398
    [Abstract] [Full Text] [Related]

  • 3. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R.
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G, Linde A, Ringdén O, Wahren B.
    J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
    [Abstract] [Full Text] [Related]

  • 5. Comparability of M-M-R II and Priorix.
    Thaler S, Heyse J.
    Pediatr Infect Dis J; 1999 Sep; 18(9):845-6. PubMed ID: 10493361
    [No Abstract] [Full Text] [Related]

  • 6. Re: V. Usonis et al.: Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children (Infection 26 [1998] 222-226).
    Nalin D.
    Infection; 1999 Sep; 27(2):134-5. PubMed ID: 10219647
    [No Abstract] [Full Text] [Related]

  • 7. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
    Senterre J.
    Rev Med Liege; 1999 Feb; 54(2):122-4. PubMed ID: 10221066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE.
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, Soncini R.
    Vaccine; 2000 Jun 15; 18(25):2796-803. PubMed ID: 10812221
    [Abstract] [Full Text] [Related]

  • 13. Gianotti-Crosti syndrome as a result of vaccination and Epstein-Barr virus infection.
    Lacour M, Harms M.
    Eur J Pediatr; 1995 Aug 15; 154(8):688-9. PubMed ID: 7588978
    [No Abstract] [Full Text] [Related]

  • 14. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A, Gerike E.
    Vaccine; 2000 Jan 31; 18(14):1382-92. PubMed ID: 10618536
    [Abstract] [Full Text] [Related]

  • 15. Acute idiopathic thrombocytopenic purpura following combined vaccination against measles, mumps, and rubella.
    Chang SK, Farrell DL, Dougan K, Kobayashi B.
    J Am Board Fam Pract; 1996 Jan 31; 9(1):53-5. PubMed ID: 8770810
    [No Abstract] [Full Text] [Related]

  • 16. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR.
    Pediatr Infect Dis J; 1996 Aug 31; 15(8):687-92. PubMed ID: 8858673
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
    Feldman S, Andrew M, Norris M, McIntyre B, Iyer R.
    Clin Infect Dis; 1998 Aug 31; 27(2):388-90. PubMed ID: 9709893
    [Abstract] [Full Text] [Related]

  • 19. Intrathecal rubella antibodies in an adolescent with Guillain-Barré syndrome after mumps-measles-rubella vaccination.
    Mühlebach-Sponer M, Zbinden R, da Silva VA, Gnehm HE.
    Eur J Pediatr; 1995 Feb 31; 154(2):166. PubMed ID: 7720751
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.